Navigation Links
TAK-390MR Phase 3 data presented at Digestive Disease Week
Date:5/19/2008

SAN DIEGO, Calif. May 18, 2008 TAP Pharmaceutical Products Inc. today reported results from three pivotal Phase 3 studies evaluating investigational new drug TAK-390MR, the first proton pump inhibitor (PPI) with an innovative dual delayed release technology, in healing patients with erosive esophagitis (EE) and in maintenance of healed EE. The data were presented at the Digestive Disease Week (DDW) annual meeting in San Diego.

The innovative dual delayed release technology delivers TAK-390MR in two separate releases, which is a first in the PPI class and makes TAK-390MR a very interesting potential future treatment option, said Dr. David Peura, professor of medicine, University of Virginia Health System, past president of the American Gastroenterological Association.

Data from the two separate EE healing studies demonstrated that patients treated with TAK-390MR 60 mg and 90 mg experienced higher overall healing after eight weeks, versus patients taking lansoprazole 30 mg. In addition, data from a six-month maintenance of healed EE study demonstrated that patients treated with TAK-390MR 30 mg and 60 mg experienced statistically significant overall maintenance and symptom relief over placebo.

Healing of Erosive Esophagitis Studies

TAK-390MR was compared to lansoprazole in two identically designed, double-blind, randomized, controlled trials in patients with confirmed EE. A total of 4,092 patients were enrolled in the two global studies. The primary objective was to evaluate overall healing rates over eight weeks after once-daily administration of TAK-390MR 60 mg or 90 mg or lansoprazole 30 mg. The results for each study were analyzed using life table and crude rate methods.

Results from these trials demonstrated that TAK-390MR 60 mg and 90 mg produced consistently high healing rates for patients with EE. In one study, the life table analysis showed that 93 percent and 95 percent of TAK-390MR patients (60 mg a
'/>"/>

Contact: Kelly Thornicroft
kthronicroft@wcpglobal.com
773-405-4515
WeissComm Partners
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. Ovation further advances development pipeline with new phase III epilepsy study
2. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
3. Mannatech Launches Phase One of New Sales and Training Tools
4. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
5. Manic phase of bipolar disorder benefits from breast cancer medication
6. ARIZONA METH PROJECT Unveils Arizonas Anti-Meth Youth Pledge and Kicks Off Phase Two of Public Awareness Campaign
7. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
8. Alexza to Initiate the First Phase 3 Trial for AZ-004 (Staccato(R) Loxapine) in Late Q1 2008
9. Iomai Patch-Based Vaccine Cut Rate of Travelers Diarrhea by 75 Percent in Phase 2 Field Study
10. MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R)
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... 2014 International efforts to ... epidemic are receiving further support from recent ... organizations (NGOs) and other charitable organizations. While ... emergency responders, patients and others can immediately ... CmTP MediDefense system , which includes ...
(Date:12/22/2014)... York, NY (PRWEB) December 22, 2014 ... 2014 stronger than ever, having invested more than ... injured service members, veterans and their families. , ... for nearly a dozen nonprofits, helping with: veteran ... nursing scholarships; and life-coaches for severely injured veterans. ...
(Date:12/22/2014)... Naples, Florida (PRWEB) December 22, 2014 ... this holiday season, the gift of health and vitality. ... is offering its three top-selling anti-aging formulas in special ... with free rush delivery. , Each bottle contains ... digestion, areas that don't work as well as we ...
(Date:12/22/2014)... December 22, 2014 Xarelto Lawsuit ... panel of judges has granted a request to centralize ... U.S. District Court, Eastern District of Louisiana. The U.S. ... on December 12 to transfer over 50 Xarelto cases–21 ... to the Louisiana court for consolidation under U.S. District ...
(Date:12/22/2014)... FL (PRWEB) December 22, 2014 Christmas is ... Beauty® has a fast and easy solution that will please: ... cards can be purchased from from $25 up to $350," ... offer 100% customer satisfaction and a wide array of skin ... no fees and no expiration dates. , Gift delivery ...
Breaking Medicine News(10 mins):Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 2Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 3Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 4Health News:Novel Biostatic Antimicrobial Technology From Clearstream-mPact Technology Partnership (CmTP) Offers Effective Protection Against Transmission of Ebola Virus 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 3Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 4Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 6Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 7Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4
... syndrome, the most commonly identified cause of cognitive impairment, ... Additionally, nearly 80 percent of fetuses with Down syndrome ... Control (CDC), in partnership with the National Down Syndrome ... current knowledge of Down syndrome, identify information gaps and ...
... researchers at George Mason University, INOVA Fairfax Hospital and ... new therapies for combating chronic diseases associated with obesity, ... American adults in 2005-06 according to the Centers for ... from morbidly obese patients undergoing weight loss surgery, the ...
... Medical,Corporation (Nasdaq: ROCM ) today announced operating results ... The Company reported record sales of $9,512,000 for ... of last year. The Company,also reported quarterly net income ... or $.06 per diluted share for the fourth quarter ...
... Profit Margin ... improves to 76%, CLEVELAND, Nov. 6 ... focused on global,eClinical solutions for the clinical trials industry, today reported its,operating ... For the three months ended September 30, 2008, revenue increased 12%,compared to ...
... ... Expectations, DENVER, Nov. 6 Air Methods ... 2008.,Revenue increased 32% to $133.8 million from $101.5 million in the year-ago,quarter. ... million in the prior-year nine-month period., For the quarter, net income ...
... a workplace chemical are often to blame, experts say ... variety of substances can cause the skin condition known ... with proper diagnosis and treatment, experts say. , Contact ... skin resulting from contact with a chemical, biologic or ...
Cached Medicine News:Health News:Melanin production discovered in fat tissue 2Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 2Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 3Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 4Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 5Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 6Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 7Health News:Rochester Medical Reports Record Fourth Quarter Sales and Record Annual Sales 8Health News:DATATRAK International, Inc. Announces 2008 Third Quarter and Nine Month Operating Results 2Health News:DATATRAK International, Inc. Announces 2008 Third Quarter and Nine Month Operating Results 3Health News:DATATRAK International, Inc. Announces 2008 Third Quarter and Nine Month Operating Results 4Health News:DATATRAK International, Inc. Announces 2008 Third Quarter and Nine Month Operating Results 5Health News:DATATRAK International, Inc. Announces 2008 Third Quarter and Nine Month Operating Results 6Health News:DATATRAK International, Inc. Announces 2008 Third Quarter and Nine Month Operating Results 7Health News:DATATRAK International, Inc. Announces 2008 Third Quarter and Nine Month Operating Results 8Health News:DATATRAK International, Inc. Announces 2008 Third Quarter and Nine Month Operating Results 9Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 2Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 3Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 4Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 5Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 6Health News:Air Methods Reports 3Q2008 Results and 4Q2008 Update 7Health News:Dermatitis Can Have Many Causes 2
(Date:12/22/2014)... , Dec. 22, 2014  Mark Farrah ... brief providing a summary of the 2015 marketplace ... enrollment trends.  According to a ... Planning and Evaluation, Department of Health and Human ... enrolled in individual medical plans through the Marketplace ...
(Date:12/22/2014)... -- Pfenex Inc. (NYSE MKT: PFNX) today announced the IND ... and is now open and that this program has ... and Human Services (HHS), through the Biomedical Advanced Research ... pleased to have the IND now active for our ... in our company,s partnership with BARDA as we continue ...
(Date:12/22/2014)... , Dec. 22, 2014 TWi Biotechnology, ... of Allowance for AC-201, TWi Biotechnology,s lead drug ... China for patent application ... pharmaceutically acceptable salts, active metabolite for treatment of ... methods of treatment using AC-201 for type II ...
Breaking Medicine Technology:Insights into the Marketplace and Individual Market Growth 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 2TWi Biotechnology Receives Notice of Patent Allowance for Its Lead Drug Candidate AC-201 for the Indication of Type II Diabetes in China 3
... DOTmed, the leading public medical equipment marketplace, and the ... have been selected by the Mid-Atlantic Group Network of Shared ... used medical equipment and idle assets. MAGNET was created ... in the niche market of capital equipment. , Derwood B. ...
... Nov. 5 BioMarin Pharmaceutical Inc. (Nasdaq: BMRN ... Trademark Office has issued a patent covering the approved ... treatment of phenylketonuria (PKU). The patent expires in ... based on the discovery that food increases the bioavailability ...
Cached Medicine Technology:MAGNET Selects DOTmed.com to Assist Members in Sale of Used Medical Equipment and Idle Assets 2United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food 2United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food 3United States Patent Office Issues Patent Covering the Approved Administration of Kuvan With Food 4
... (6 size AA required). Fast, Lightweight Strain ... ozt, GN, dwt, mom, dwt, tael), Specific ... functions, Auto Print. Optional hook (321-34532-03) available ... be ordered for AC Operation of ELB. ...
60 month warranty, constructed entirely of aluminum alloy, allows the selection of 11 units of measure....
60 month warranty, constructed entirely of aluminum alloy, allows the selection of 11 units of measure....
Guaranteed leak-proof , Teflon coating is impervious to corrosive materials , Shock-resistant , NBS tolerances of accuracy , Thermometers are 225 mm long with an immersion length of 35 mm ...
Medicine Products: